Cagrilintide Injection

Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of cagrilintide injection in China. Welcome to wholesale bulk high quality cagrilintide injection for sale here from our factory. Good service and reasonable price are available.

The value of Cagrilintide injection in the field of cardiovascular diseases primarily relies on its fixed-dose combination therapy, CagriSema, which achieves cardiovascular protection, supports disease treatment, and incorporates an optimized safety profile through multi-pathway mechanisms. Based on the five selected core points, the following provides a detailed elaboration, clarifying the underlying principles, clinical relevance, and practical significance of each point, with a consistent focus on cardiovascular applications.

 

Our Products Form

 

Cagrilintide COA

Certificate of Analysis
Compound name	Cagrilintide
Grade	Pharmaceutical grade
CAS No.	1415456-99-3
Quantity	30g
Packaging standard	PE bag+Al foil bag
Manufacturer	Shaanxi BLOOM TECH Co., Ltd
Lot No.	202501090068
MFG	Jan 9th 2025
EXP	Jan 8th 2028
Structure	N/A
Item	Enterprise standard	Analysis result
Appearance	White or almost white powder	Conformed
Water content	≤5.0%	0.54%
Loss on drying	≤1.0%	0.42%
Heavy Metals	Pb≤0.5ppm	N.D.
	As≤0.5ppm	N.D.
	Hg≤0.5ppm	N.D.
	Cd≤0.5ppm	N.D.
Purity (HPLC)	≥99.0%	99.98%
Single impurity	<0.8%	0.52%
Total microbial count	≤750cfu/g	95
E. Coli	≤2MPN/g	N.D.
Salmonella	N.D.	N.D.
Ethanol (by GC)	≤5000ppm	500ppm
Storage	Store in a sealed, dark, and dry place below -20°C

(I)Downregulation of Sympathetic Nervous System Activity Mediated by Weight Loss:

 

Obesity is often accompanied by overactivation of the sympathetic nervous system, a significant trigger for increased blood pressure and accelerated heart rate. Sympathetic nerve excitation promotes vasoconstriction and raises heart rate, thereby increasing vascular resistance and cardiac load. Long-term activation can also lead to abnormal activation of the RAAS (renin-angiotensin-aldosterone system), creating a vicious cycle of elevated blood pressure.

 

By activating central amylin receptors, cagrilintide injection synergizes with the GLP-1 receptor agonist effect of semaglutide to suppress appetite and reduce food intake, achieving substantial weight loss.This weight reduction directly alleviates the overactivation of the sympathetic nervous system.

Subsequently slowing heart rate, lowering systemic vascular resistance, and reducing RAAS activation. It also blocks angiotensin II-mediated vasoconstriction and water-sodium retention, addressing the pathological basis of hypertension at its source. 

(II)Improvement of Endothelial Function and Promotion of Nitric Oxide (NO) Release:

The vascular endothelium plays a critical role in regulating vascular tone and maintaining vascular homeostasis. Metabolic abnormalities such as obesity, hyperlipidemia, and hyperglycemia can impair vascular endothelial function, leading to decreased endothelium-dependent vasodilation, increased peripheral vascular resistance, and ultimately elevated blood pressure.

Cagrilintide helps restore damaged vascular endothelial cells by improving metabolic disorders and reducing endothelial inflammation, thereby promoting the synthesis and release of nitric oxide (NO) by endothelial cells. NO is a key vasodilator in the body, relaxing vascular smooth muscles, dilating peripheral blood vessels, and effectively reducing peripheral vascular resistance, which contributes to lowering blood pressure. Additionally, it enhances the anti-thrombotic and anti-proliferative functions of the vascular endothelium, reducing hypertension-related vascular damage. 

(III)Reducing Water and Sodium Retention, Decreasing Blood Volume Load:

The cardioprotective effects of it primarily revolve around two core pathways: optimizing myocardial energy metabolism and inhibiting myocardial fibrosis. These mechanisms target key pathological processes such as myocardial ischemia and ventricular remodeling, offering potential as adjunctive therapy for conditions like coronary heart disease and heart failure. The details are as follows:

 

 

Improving Myocardial Energy Metabolism, Optimizing Fatty Acid and Glucose Utilization Efficiency, and Reducing Myocardial Ischemia-Reperfusion Injury.

The normal function of myocardial cells depends on adequate energy supply. Metabolic abnormalities such as obesity and diabetes can disrupt myocardial energy metabolism-excessive fatty acid accumulation increases myocardial burden, while reduced glucose utilization efficiency leads to insufficient energy supply.This metabolic disturbance is exacerbated during myocardial ischemia (e.g., myocardial infarction), worsening cardiomyocyte damage and even leading to cell necrosis.

It can modulate the metabolic pathways of cardiomyocytes, optimize the balance between fatty acid and glucose utilization, reduce the toxic effects of excessive fatty acids on the myocardium, and enhance the efficiency of glucose oxidation for energy production, thereby providing stable and sufficient energy to myocardial cells. Additionally, during myocardial ischemia-reperfusion (e.g., after thrombolysis or stent placement), this can mitigate cardiomyocyte damage by inhibiting oxidative stress and inflammatory responses, reducing oxygen free radical injury, decreasing the extent of myocardial necrosis after reperfusion, improving functional recovery, and lowering the risk of post-infarction heart failure.

Inhibiting Myocardial Fibrosis, Reducing Collagen Deposition, Improving Ventricular Remodeling, and Lowering the Risk of Heart Failure.

Myocardial fibrosis is a central pathological process in the progression of various cardiovascular diseases (e.g., hypertension, myocardial infarction, cardiomyopathy) to heart failure. Prolonged increases in myocardial pressure load and inflammatory stimulation lead to abnormal proliferation of cardiac fibroblasts and excessive collagen deposition in myocardial tissue, resulting in myocardial stiffness, reduced compliance, and subsequent ventricular remodeling (ventricular hypertrophy and chamber enlargement), ultimately leading to heart failure.

Cagrilintide injection can inhibit the proliferation of cardiac fibroblasts and collagen synthesis, reduce collagen deposition in myocardial tissue, slow the progression of myocardial fibrosis, and improve myocardial compliance and elasticity. Furthermore, its effects on weight loss and blood pressure reduction alleviate long-term cardiac load, preventing further progression of ventricular remodeling. This makes it particularly suitable for long-term myocardial protection in high-risk populations, such as those with obesity combined with hypertension or post-myocardial infarction conditions.

Obesity is a significant risk factor for hypertension, and patients with obesity combined with hypertension face greater difficulty in blood pressure control and a substantially higher risk of cardiovascular complications compared to those with hypertension alone. This drug serves as an adjunctive treatment specifically targeting the core challenges of obesity-associated hypertension.

As an adjunct to lifestyle interventions and conventional antihypertensive medications, particularly suitable for patients with resistant hypertension:
For patients with obesity and hypertension, lifestyle interventions (such as dietary control and increased physical activity) form the foundation of treatment, yet long-term adherence is challenging, and lifestyle changes alone often fail to achieve optimal blood pressure reduction.

While conventional antihypertensive medications (e.g., diuretics, ACEIs/ARBs, calcium channel blockers) can lower blood pressure, some patients-especially those with resistant hypertension-require multiple medications to achieve target levels, and these drugs do not address obesity as the underlying cause. 

Cagrilintide can serve as an adjunctive treatment, working synergistically with lifestyle interventions and conventional antihypertensive medications. Its weight-loss effects address the root causes of obesity-related metabolic dysregulation and blood pressure elevation, while its multi-pathway antihypertensive mechanisms enhance the efficacy of conventional drugs. This approach is particularly beneficial for patients with resistant hypertension (defined as those unable to achieve blood pressure control despite using three or more conventional antihypertensive medications).

Through such synergistic therapy, it may help reduce the number and dosage of conventional antihypertensive medications, minimize adverse effects associated with polypharmacy (such as electrolyte imbalances and renal impairment), and improve patient adherence to treatment. 

Cagrilintide represents a promising adjunctive therapeutic strategy for managing complex cardiovascular conditions, including obesity-related hypertension and peripheral arterial disease. By leveraging its dual-action mechanisms-multi-pathway blood pressure modulation and direct cardioprotective effects-it addresses both the physiological and metabolic underpinnings of these disorders. Specifically, its ability to regulate blood pressure through multiple pathways, such as reducing sympathetic nervous system activity and improving endothelial function, complements existing treatments and targets underlying drivers of cardiovascular risk. Furthermore, its cardioprotective properties, which include optimizing myocardial energy metabolism and inhibiting fibrosis, offer additional benefits in preventing disease progression and improving cardiac outcomes.

The optimized safety profile of Cagrilintide, demonstrated in clinical studies to date, provides a strong foundation for its long-term use in cardiovascular protection. Its favorable tolerability and low risk of adverse effects make it a viable option for chronic management, particularly in populations with comorbidities such as obesity and diabetes. Ongoing and future clinical trials are crucial to further validate its efficacy, refine its therapeutic applications, and elucidate its long-term impact on cardiovascular morbidity and mortality. As research advances, it is poised to play an increasingly significant role in the evolving landscape of cardiovascular disease management.

How often should I take this drug?

Once-a-week cagrilintide is effective for weight management in overweight and obese patients | 2 Minute Medicine.

What is the strongest weight loss injection?

This research shows that, while both weight-loss injections can help you lose a lot of weight if you have obesity, tirzepatide (Mounjaro) may be more effective than semaglutide (Wegovy). For people living with obesity, losing more weight may further reduce their risk of heart attack or stroke.

Hot Tags: cagrilintide injection, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale